EUVIMEDEUVIMED entdecken
Crossref

Effectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children

Jesús Castilla iD, Manuel García Cenoz iD, Raquel Abad, Laura Sánchez-Cambronero, Nicola Lorusso iD, Conchita Izquierdo, Soledad Cañellas Llabrés, Javier Roig, Alberto Malvar iD, Fernando González Carril, An L D Boone iD, Jaime Pérez Martín und 34 weitere

New England Journal of Medicine · 2023

DOI: 10.1056/nejmoa2206433 ↗

Kurz gefasst

Fachartikel in der Zeitschrift New England Journal of Medicine, 2023. Verfasst von Jesús Castilla und 45 weiteren Autor:innen. Beteiligte Einrichtung: From Instituto de Salud Pública de Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona (J.C., M.G.C., A.B.), Consorcio de Investigació…. Hauptthemen laut MEDLINE: Meningococcal Infections, Meningococcal Vaccines, Neisseria meningitidis, Serogroup B. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In September 2015, the four-component, protein-based meningococcal serogroup B vaccine (4CMenB; Bexsero) became available for private purchase in Spain. METHODS: We conducted a nationwide matched case-control study to assess the effectiveness of 4CMenB in preventing invasive meningococcal disease in children. The study included all laboratory-confirmed cases of invasive meningococcal disease in children younger than 60 months of age between October 5, 2015, and October 6, 2019, in Spain. Each case patient was matched with four controls according to date of birth and province. 4CMenB vaccination status of the case patients and controls was compared with the use of multivariate conditional logistic regression. RESULTS: We compared 306 case patients (243 [79.4%] with serogroup B disease) with 1224 controls. A total of 35 case patients (11.4%) and 298 controls (24.3%) had received at least one dose of 4CMenB. The effectiveness of complete vaccination with 4CMenB (defined as receipt of at least 2 doses, administered in accordance with the manufacturer's recommendations) was 76% (95% confidence interval [CI], 57 to 87) against invasive meningococcal disease caused by any serogroup, and partial vaccination was 54% (95% CI, 18 to 74) effective. Complete vaccination resulted in an effectiveness of 71% (95% CI, 45 to 85) against meningococcal serogroup B disease. Vaccine effectiveness with at least one dose of 4CMenB was 64% (95% CI, 41 to 78) against serogroup B disease and 82% (95% CI, 21 to 96) against non-serogroup B disease. With the use of the genetic Meningococcal Antigen Typing System, serogroup B strains that were expected to be covered by 4CMenB were detected in 44 case patients, none of whom had been vaccinated. CONCLUSIONS: Complete vaccination with 4CMenB was found to be effective in preventing invasive disease by serogroup B and non-serogroup B meningococci in children younger than 5 years of age.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Meningococcal InfectionsMeningococcal VaccinesNeisseria meningitidis, Serogroup BChildHumansInfantCase-Control StudiesNeisseria meningitidisSpain

Substanzen

Meningococcal Vaccines4CMenB vaccine

Autor:innen und Institutionen

  • From Instituto de Salud Pública de Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona (J.C., M.G.C., A.B.), Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública (J.C., M.G.C., C.I…

ORCID-Profile: Jesús Castilla, Manuel García Cenoz, Nicola Lorusso, Alberto Malvar, An L D Boone, Rafael Ruiz-Montero

Zitieren

APA

Castilla, J., García Cenoz, M., Abad, R., Sánchez-Cambronero, L., Lorusso, N., Izquierdo, C., Cañellas Llabrés, S., Roig, J., Malvar, A., González Carril, F., Boone, A. L. D., Pérez Martín, J., Rodríguez Recio, M. J., Galmés, A., Caballero, A., García Rojas, A., Juanas, F., Nieto, M., Viloria Raymundo, L. J., …, & Barricarte, A. (2023). Effectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2206433

Vancouver

Castilla J, García Cenoz M, Abad R, Sánchez-Cambronero L, Lorusso N, Izquierdo C, et al. Effectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children. New England Journal of Medicine. 2023. doi:10.1056/nejmoa2206433

BibTeX
@article{Castilla2023,
  author = {Castilla, Jesús and García Cenoz, Manuel and Abad, Raquel and Sánchez-Cambronero, Laura and Lorusso, Nicola and Izquierdo, Conchita and Cañellas Llabrés, Soledad and Roig, Javier and Malvar, Alberto and González Carril, Fernando and Boone, An L D and Pérez Martín, Jaime and Rodríguez Recio, M Jesús and Galmés, Antònia and Caballero, Arturo and García Rojas, Amós and Juanas, Felipe and Nieto, Mercedes and Viloria Raymundo, Luis J and Martínez Ochoa, Eva and Rivas, Ana I and Castrillejo, Daniel and Moreno Pérez, David and Martínez, Ana and Borràs, Eva and Sánchez Gómez, Amaya and Pastor, Eliseo and Nartallo, Victoria and Arteagoitia, José M and Álvarez-Fernández, Blanca and García Pina, Rocío and Fernández Arribas, Socorro and Vanrell, Joana and García Hernández, Sara and Mendoza, Rita M and Méndez, Manuel and López-Tercero, M Mar and Fernández-Rodríguez, Ángela and Blanco, Ángela and Carrillo de Albornoz, F Javier and Ruiz Olivares, José and Ruiz-Montero, Rafael and Limia, Aurora and Navarro-Alonso, José A and Vázquez, Julio A and Barricarte, Aurelio},
  title = {Effectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children},
  journal = {New England Journal of Medicine},
  year = {2023},
  doi = {10.1056/nejmoa2206433}
}
Kostenlos starten →